Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2018

View Archived Issues

Tumor T cells mostly just rubbernecking

"Noncoding" regions produce tumor antigens

MTH1 expression levels predict breast cancer prognosis

Inflammasome inhibition is promising antibacterial therapy

Kiniksa presents interim phase II data for rilonacept and initiates phase III RHAPSODY study

ABHD12 regulates immunostimulatory lipid pathways in vivo

Novel pyrimidopyrimidinone derivative JND-3229 inhibits EGFR C797S mutant

CEPI and Imperial College London partner to develop saRNA vaccine platform

FDA clears IND for Y-mAbs' bispecific GD2 antibody

Almirall and X-Chem to develop oral dermatological treatments

First subject enrolled in phase I/IIa study of AR-501

Novel model of ALS discounts protein transmission hypothesis in disease pathogenesis

Phase IIb T-Force GOLD study of valbenazine does not meet primary endpoint

JMX-0293 inhibits tumor growth in preclinical models of TNBC

Praxis Precision Medicines investigates repurposing sodium channel blocker for epilepsy

Phase II study of bermekimab in atopic dermatitis meets endpoints

Nflection Therapeutics discovers MAPKK 1 inhibitors

Prostanoid EP2/EP4 receptor antagonists patented by Idorsia Pharmaceuticals

Mutation in the telomere length control protein TZAP is associated with poor breast cancer prognosis

Sosei Heptares initiates first-in-human study with mGlu5 NAM HTL-0014242

Denali Therapeutics presents new RIPK1 inhibitors

KDM5B inhibitors divulged by the University of Texas

Superb Wisdom describes new resiquimod derivatives

No signs of clinical activity at 6 months with rAAV2tYF-CB-hRS1 in X-linked retinoschisis

Merck & Co. and Instituto Butantan to develop dengue vaccines

Entera Bio and Amgen collaborate on oral large molecule programs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...